Total Payments
$99,194
2024 Payments
$21,756
Companies
24
Transactions
149
Medicare Patients
758
Medicare Billing
$77,481
Payment Breakdown by Category
Consulting$61,844 (62.3%)
Other$16,717 (16.9%)
Travel$12,660 (12.8%)
Food & Beverage$5,751 (5.8%)
Research$2,222 (2.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $61,844 | 29 | 62.3% |
| Travel and Lodging | $12,660 | 28 | 12.8% |
| Honoraria | $8,815 | 2 | 8.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,902 | 5 | 8.0% |
| Food and Beverage | $5,751 | 80 | 5.8% |
| Unspecified | $2,222 | 5 | 2.2% |
Payments by Type
General
$96,972
144 transactions
Research
$2,222
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $23,606 | 26 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $13,618 | 26 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $13,222 | 20 | $0 (2019) |
| Mirum Pharmaceuticals, Inc. | $11,949 | 9 | $0 (2024) |
| Kastle Therapeutics LLC | $10,008 | 6 | $0 (2017) |
| Daiichi Sankyo Inc. | $4,750 | 9 | $0 (2018) |
| Akcea Therapeutics, Inc. | $4,000 | 2 | $0 (2021) |
| Kaneka Medical America LLC | $3,000 | 2 | $0 (2023) |
| Retrophin, Inc. | $2,515 | 2 | $0 (2018) |
| Kaneka Pharma America LLC | $2,279 | 7 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21,756 | 29 | Mirum Pharmaceuticals, Inc. ($11,949) |
| 2023 | $14,834 | 24 | Regeneron Healthcare Solutions, Inc. ($11,244) |
| 2022 | $4,691 | 16 | Regeneron Healthcare Solutions, Inc. ($2,140) |
| 2021 | $11,059 | 9 | Akcea Therapeutics, Inc. ($4,000) |
| 2020 | $4,425 | 3 | SANOFI PASTEUR INC. ($2,244) |
| 2019 | $13,915 | 16 | Regeneron Pharmaceuticals, Inc. ($7,810) |
| 2018 | $11,302 | 31 | Daiichi Sankyo Inc. ($4,750) |
| 2017 | $17,211 | 21 | Kastle Therapeutics LLC ($10,008) |
All Payment Transactions
149 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Consulting Fee | Cash or cash equivalent | $4,950.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Consulting Fee | Cash or cash equivalent | $1,237.50 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Consulting Fee | Cash or cash equivalent | $412.50 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Consulting Fee | Cash or cash equivalent | $412.50 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $8.24 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $8.24 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $42.86 | General |
| Category: Cardiology | ||||||
| 11/01/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $122.98 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/04/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $159.60 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/01/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $286.22 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/01/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $159.60 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 09/20/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $667.45 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 09/20/2024 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Travel and Lodging | In-kind items and services | $25.50 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/02/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $97.78 | General |
| Category: Cardiology | ||||||
| 06/01/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $138.85 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 05/30/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $5,582.50 | General |
| Category: Alagille syndrome | ||||||
| 05/30/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Alagille syndrome | ||||||
| 05/30/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Consulting Fee | Cash or cash equivalent | $1,540.00 | General |
| Category: Alagille syndrome | ||||||
| 05/30/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $1,343.19 | General |
| Category: Alagille syndrome | ||||||
| 05/30/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $215.46 | General |
| Category: Alagille syndrome | ||||||
| 05/30/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $98.76 | General |
| Category: Alagille syndrome | ||||||
| 05/30/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $80.65 | General |
| Category: Alagille syndrome | ||||||
| 05/30/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Food and Beverage | Cash or cash equivalent | $69.94 | General |
| Category: Alagille syndrome | ||||||
| 05/30/2024 | Mirum Pharmaceuticals, Inc. | Livmarli (Drug) | Travel and Lodging | Cash or cash equivalent | $18.72 | General |
| Category: Alagille syndrome | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $1,381 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA UNDERGOING LIPID APHERESIS THERAPY | Regeneron Pharmaceuticals, Inc. | $451.61 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUSFAMILIAL HYPERCHOLESTEROLEMIA | Regeneron Pharmaceuticals, Inc. | $250.30 | 1 |
| A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SAFETY AND EFFICACY, FOLLOWING REPEAT-DOSE ADMINISTRATION OF EVINACUMAB (ANTI-ANGPTL3) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG) AT RISK FOR ACUTE PANCREATITIS | Regeneron Pharmaceuticals, Inc. | $138.29 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 195 | 249 | $90,341 | $19,705 |
| 2022 | 3 | 201 | 259 | $74,860 | $20,237 |
| 2021 | 3 | 171 | 227 | $64,284 | $19,323 |
| 2020 | 3 | 191 | 238 | $60,839 | $18,216 |
Total Patients
758
Total Services
973
Medicare Billing
$77,481
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 147 | 193 | $67,234 | $14,254 | 21.2% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 30 | 38 | $12,227 | $2,864 | 23.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $10,880 | $2,588 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 131 | 173 | $45,297 | $12,119 | 26.8% |
| 99358 | Extended patient service without direct patient contact, first hour | Office | 2022 | 41 | 57 | $15,534 | $4,279 | 27.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 29 | 29 | $14,029 | $3,839 | 27.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 81 | 114 | $26,522 | $8,565 | 32.3% |
| 99358 | Prolonged patient service without direct patient contact first hour | Office | 2021 | 50 | 73 | $19,754 | $5,970 | 30.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 40 | 40 | $18,008 | $4,788 | 26.6% |
| 99358 | Prolonged patient service without direct patient contact first hour | Office | 2020 | 108 | 143 | $38,324 | $12,185 | 31.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 69 | 81 | $16,389 | $4,073 | 24.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 14 | 14 | $6,126 | $1,957 | 32.0% |
About Dr. Paul Duell, MD
Dr. Paul Duell, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265448864.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Duell, MD has received a total of $99,194 in payments from pharmaceutical and medical device companies, with $21,756 received in 2024. These payments were reported across 149 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($61,844).
As a Medicare-enrolled provider, Duell has provided services to 758 Medicare beneficiaries, totaling 973 services with total Medicare billing of $77,481. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Portland, OR
- Active Since 08/01/2006
- Last Updated 07/24/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1265448864
Products in Payments
- EVKEEZA (Biological) $27,723
- Livmarli (Drug) $11,949
- KYNAMRO (Drug) $10,008
- PRALUENT (Biological) $8,082
- PRALUENT (Drug) $6,938
- NO PRODUCT DISCUSSED (Drug) $6,262
- Welchol (Drug) $4,750
- (810) Chenodal (Drug) $2,515
- JUXTAPID (Drug) $2,150
- Vascepa (Drug) $2,066
- LIPOSORBER (Device) $1,500
- Liposober (Device) $1,500
- PRALUENT ALIROCUMAB INJECTION (Biological) $1,420
- FARXIGA (Drug) $930.00
- Repatha (Biological) $913.10
- Livalo (Drug) $429.34
- NEXLETOL (Drug) $387.33
- JANUVIA (Drug) $239.12
- LEQVIO (Drug) $122.98
- XARELTO (Drug) $121.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Portland
Mr. Michael Mcclung, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.6M
Endocrinology, Diabetes & Metabolism $1.6M
James Neifing, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $475,019
Endocrinology, Diabetes & Metabolism $475,019
Maria Fleseriu, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $418,716
Endocrinology, Diabetes & Metabolism $418,716
Rodica Busui, Md, Phd, MD, PHD
Endocrinology, Diabetes & Metabolism — Payments: $211,479
Endocrinology, Diabetes & Metabolism $211,479
Jonathan Purnell, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $209,631
Endocrinology, Diabetes & Metabolism $209,631
Nancy Curosh, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $194,307
Endocrinology, Diabetes & Metabolism $194,307